Domainex and UCB successfully complete their first collaborative project
Mark Bushfield of UCB commented: "The construct provided by Domainex has all the characteristics that we were looking for, and I am sure this would not have been found using any other method. We are currently in discussions to agree the next stage of our collaboration".
Eddy Littler, CEO of Domainex, added: "Our technology is unique, proprietary and offers an opportunity to work on targets hitherto unavailable to the pharmaceutical industry. We are delighted that our collaboration with UCB has already come to fruition and we look forward to working together on future projects".
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.